Chiesi Wins EU Nod For COPD Triple Combo, But Partner Is Predicted For Launch
Chiesi's triple combination therapy for COPD, Trimbow, has secured its first approval globally after winning a positive recommendation from the CHMP for its use in Europe – but analysts expect a respiratory partner will be required to launch the product.
You may also be interested in...
Ahead of a regulatory verdict in the US, GSK's triple combination therapy for COPD, Trelegy Ellipta, has won a positive recommendation in Europe.
There has been some criticism of the recent update to COPD management guidelines published by GOLD, with concern over the how much of the changes are based on clinical evidence.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.